Abstract 412P
Background
To study of cytogenetic changes in peripheral blood lymphocytes of patients with osteosarcoma.
Methods
Studies were conducted in peripheral blood samples of 196 patients with osteosarcoma (OS) aged from 10 to 45 years. The primary cytogenetic study of patients was carried out before their clinical examination.
Results
The analysis showed that after chemotherapy, 59.5% of patients had a full and partial effect. At 46.2%, the background level of chromosomal abnormalities was less than 5% (discriminatory or dividing level), but 2.5 times higher than the average level of chromosomal abnormalities in healthy individuals. The lack of effect was observed in 40.5% of patients, and their background chromosomal abnormalities were higher than discriminatory (5%) and 7.5 times higher than in healthy individuals. A comparative analysis of the effectiveness of the treatment and the average background level of Cr-disorders among patients in this group showed that 46.2% of patients with a positive effect from chemotherapy had an average level of Cr-disorders in peripheral blood lymphocytes 2.4 times lower, than in patients with a lack of effect from this therapy.
Conclusions
The analysis showed that in the absence of the effect of the treatment carried out, the background indicators of chromosomal aberrations are significantly higher than in healthy individuals or in individuals with good clinical effect. Consequently, according to the level of chromosome aberrations in the peripheral blood lymphocytes of patients with OS identified before the start of treatment, the therapeutic effect can be predicted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ronc.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract